Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3205919 | 0.98 | CA12 (0.44) | CA12CA2CA9TAAR1TP53 | |
| Hydrochloric Acid SCHEMBL27301016 | 0.98 | CA12 (0.44) | CA12CA2CA9TAAR1TP53 | |
| SCHEMBL11044440 | 0.87 | CA12 (0.50) | CA12CA2CA9TAAR1SIGMAR1 | |
| SCHEMBL96161 | 0.86 | MAPT (0.55) | CA12CA2CA9TAAR1TP53 | |
| SCHEMBL94623 | 0.84 | NPC1 (0.49) | CA12CA2CA9SIGMAR1MAPT | |
| Hydrochloric Acid SCHEMBL8801549 | 0.84 | MAPT (0.53) | CA12CA2CA9TAAR1TP53 | |
| Ammonia Solution, Strong SCHEMBL11366087 | 0.84 | MAPT (0.53) | CA12CA2CA9TAAR1TP53 | |
| SCHEMBL13481182 | 0.83 | ALDH1A1 (0.48) | TAAR1SIGMAR1HTTTSHRALDH1A1 | |
| SCHEMBL6501802 | 0.82 | NPC1 (0.51) | SIGMAR1MAPTTRPV1 | |
| SCHEMBL94910 | 0.82 | NPC1 (0.51) | SIGMAR1MAPTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| CN-113109417-B | Ion mobility spectrometer for rapidly detecting icetoxin in presence of nicotine | 中国科学院合肥物质科学研究院 | 2024-07-05 | — | — | CN | claimed |
| US-20230364224-A1 | Pharmaceutical Composition For Allergen Specific Immunotherapy | HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2023-11-16 | — | — | US | claimed |
| EP-4213873-A1 | COMPOSITE SOLDER BALLS METALLISED ON THE SURFACE AND CALIBRATED FOR THE ASSEMBLY OF ELECTRONIC BOARDS | Hopitaux Universitaires de Genève (CH) | 2023-07-26 | — | — | EP | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| CN-1225452-C | Prepn. of (+)-trans-chrysanthemic acid | SUMITOMO CHEMICAL CO (JP) | 2005-11-02 | — | — | CN | claimed |
| WO-2004018368-A1 | SYNERGISTIC BIOCIDAL MIXTURES | HERCULES INCORPORATED (US) | 2004-03-04 | — | — | WO | claimed |
| US-20040035803-A1 | Synergistic biocidal mixtures | SOLENIS TECHNOLOGIES, L.P. | 2004-02-26 | — | — | US | claimed |
| US-6660858-B2 | Made by reacting a benzoxazole with a leaving group at the 2 position and a diamine of given formula | LION BIOSCIENCE AG (DE) | 2003-12-09 | — | — | US | claimed |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG (DE) | 2002-10-31 | — | — | US | claimed |
| WO-2002079753-A2 | 2-AMINOBENZOXAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-10-10 | — | — | WO | claimed |
| CN-1298862-A | Prepn. of (+)-trans-chrysanthemic acid | SUMITOMO CHEMICAL CO (JP) | 2001-06-13 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4857657-A | Preparation of hexenedioic acid diesters | RHONE-POULENC CHIMIE (FR) | 1989-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | BCAT2, IL4I1, BCAT1 | CA12 4317/4885CA2 3523/4885CA9 3104/4885 |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | CA12 82/4885CA2 1408/4885CA9 801/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | CA12 82/4885CA2 1408/4885CA9 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.